President Donald Trump signed an executive order on Monday, May 5, to boost domestic production of prescription drugs and lessen reliance on foreign supply chains. The order directs the FDA to streamline approvals and increase inspections.
This decision coincides with upcoming tariffs on pharmaceuticals aimed at bolstering national security.
The U.S. currently depends on China for 95% of key ingredients in generic drugs, according to industry estimates.
The order aims to streamline FDA approvals for domestic drug manufacturing while increasing inspections and fees for foreign plants to promote local production.
